HTG Introduces the HTG EdgeSeq Pan B-Cell Lymphoma Panel
HTG Molecular Diagnostics (Nasdaq: HTGM) announced the pre-launch of its new HTG EdgeSeq Pan B-Cell Lymphoma Panel, set for commercial availability in July 2020. This research-use-only panel enables molecular characterization of aggressive lymphomas, addressing the need for better subtype identification amidst nearly 600,000 global lymphoma diagnoses annually. The panel builds on the company's existing DLBCL assay, featuring around 300 genes aimed at improving molecular subtyping. HTG's technology is pivotal for precision medicine, with significant potential for researchers and clinical applications.
- Introduction of the HTG EdgeSeq Pan B-Cell Lymphoma Panel improves molecular profiling for aggressive lymphomas.
- Expands HTG's assay portfolio, building on the successful DLBCL assay.
- Panel includes approximately 300 genes, enhancing research capabilities.
- The commercial success of the new panel is uncertain and subject to market acceptance.
- The announcement includes forward-looking statements which carry inherent risks, including potential underperformance.
TUCSON, Ariz., June 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the pre-launch introduction of its new HTG EdgeSeq Pan B-Cell Lymphoma Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory starting in July 2020.
The HTG EdgeSeq Pan B-Cell Lymphoma Panel is a research-use only panel designed to provide molecular characterization of aggressive lymphomas by allowing researchers to measure the expression of genes associated with the aggressive lymphoma transcriptome. Globally, there are nearly 600,000 new cases of lymphoma diagnosed and over 250,000 deaths from the various lymphoma subtypes annually. Correctly diagnosing lymphomas often requires 20 or more immunohistochemical (IHC) tests, and incorrect subtype classification is common. HTG’s new comprehensive HTG EdgeSeq Pan B-Cell Lymphoma Panel is designed to better facilitate identification of lymphoma subgroups addressing this important market.
“HTG has focused on lymphoma for several years, specifically diffuse large B-cell lymphoma (DLBCL) with the HTG EdgeSeq DLBCL Cell of Origin Assay EU, which obtained a CE Mark in 2016. This new panel is an extension of our DLBCL assay, developed in partnership with HTG’s Lymphoma Advisory Board, and includes approximately 300 genes focused on molecular subtyping aggressive lymphomas,” said Byron Lawson, Senior Vice President and Chief Commercial Officer. “We are excited to expand the HTG EdgeSeq assay portfolio with this new RUO panel, which will include the cell of origin signature available in HTG EdgeSeq Reveal, HTG’s web-based biostatistical analysis software tool. Together we expect these tools to enable both HTG and researchers globally to develop molecular subtyping algorithms to potentially classify various aggressive lymphomas.”
About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding when the HTG EdgeSeq Pan B-Cell Lymphoma Panel will be commercially available in kit form and as a service, HTG’s ability to commercialize the HTG EdgeSeq Pan B-Cell Lymphoma Panel, and the ability of the HTG EdgeSeq Pan B-Cell Lymphoma Panel to better facilitate identification of lymphoma subgroups and to enable HTG and researchers globally to develop molecular subtyping algorithms to potentially classify various aggressive lymphomas. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including but not limited to, the risk that the HTG EdgeSeq Pan B-Cell Lymphoma will not perform as expected. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
What is the HTG EdgeSeq Pan B-Cell Lymphoma Panel?
When will the HTG EdgeSeq Pan B-Cell Lymphoma Panel be available?
How many genes are included in the HTG EdgeSeq Pan B-Cell Lymphoma Panel?
What company is behind the HTG EdgeSeq Pan B-Cell Lymphoma Panel?
What are the expected benefits of the HTG EdgeSeq Pan B-Cell Lymphoma Panel?
